Exploring the Use of a Digital Platform for Cancer Patients to Report Their Demographics, Disease and Therapy Characteristics, Age, and Educational Disparities: An Early-Stage Feasibility Study.
age
cancer
digital health
educational disparities
patients’ characteristics
socioeconomic issues
Journal
Current oncology (Toronto, Ont.)
ISSN: 1718-7729
Titre abrégé: Curr Oncol
Pays: Switzerland
ID NLM: 9502503
Informations de publication
Date de publication:
12 08 2023
12 08 2023
Historique:
received:
01
04
2023
revised:
05
08
2023
accepted:
08
08
2023
medline:
28
8
2023
pubmed:
25
8
2023
entrez:
25
8
2023
Statut:
epublish
Résumé
The increasing burden of cancer, the development of novel therapies, and the COVID-19 pandemic have made cancer care more complex. Digital innovation was then pushed toward developing platforms to facilitate access to cancer care. Age, education, and other disparities were, however, shown to limit the use of the digital health innovation. The aim of this early-stage feasibility study was to assess whether Greek cancer patients would register at CureCancer and self-report their demographics, disease and therapy characteristics, and socioeconomic issues. The study was organized by the Hellenic Society of Medical Oncology. Patients from nine cancer centers were invited to register on the CureCancer platform and complete an anonymous questionnaire on demographics, disease and therapy characteristics, and socioeconomic issues. Patients were also encouraged to upload, in a secure area for them, their medical files and share them with their physicians. They were then asked to comment on their experience of registration and how easy it was to upload their medical files. Of the 159 patients enrolled, 144 (90.56%) registered, and 114 of those (79.16%) completed the questionnaire, suggesting that the study is feasible. Users' median age was 54.5 years, and 86.8% of them were university and high school graduates. Most patients (79.8%) reported their specific type of cancer diagnosis, and all reported their therapy characteristics. Breast and lung cancers were the most common. A total of 87 patients (76.3%) reported being on active cancer therapy, 46 (40.4%) had metastatic disease, and 51 (44.7%) received supportive care medications. Eighty-one (71.05%) patients received prior cancer therapies, and twenty-seven recalled prior supportive care medications. All patients reported visiting non-oncology Health Care Professionals during the study. Nineteen of 72 (26.39%) patients who worked prior to cancer diagnosis changed work status; 49 (42.98) patients had children under 24 years; and 16 (14%) patients lived alone. Nine (7.9%) patients were members of patient associations. Registration was "much/very much" easy for 98 (86.0%) patients, while 67 (58.8%) had difficulties uploading their files. Patients commented on the well-organized data access, improved communication, feeling safe, medication adherence, interventions from a distance, and saving time and money. Over 80% of patients "preferred the digital way". A total of 114 patients succeeded in registering on the digital platform and reporting their demographics, disease and therapy characteristics, and socioeconomic issues. Age and educational disparities were disclosed and highlighted the need for educational programs to help older people and people of lower education use digital innovation. Health care policy measures would support patients' financial burden associated with work changes, living alone, and children under 24 years old at school or college. Policy actions would motivate patients to increase their participation in patient associations. According to the evidence DEFINED framework, the number of patients, and the focus on enrollment, engagement, and user experience, the study fulfills actionability level criterion 1.
Identifiants
pubmed: 37623032
pii: curroncol30080551
doi: 10.3390/curroncol30080551
pmc: PMC10453047
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
7608-7619Références
Support Care Cancer. 2020 Oct;28(10):4589-4612
pubmed: 32533435
Support Care Cancer. 2022 Feb;30(2):1823-1830
pubmed: 34608533
Support Care Cancer. 2021 Feb;29(2):713-723
pubmed: 32444894
JCO Clin Cancer Inform. 2021 Aug;5:872-880
pubmed: 34428075
Support Care Cancer. 2022 Nov;30(11):8785-8803
pubmed: 35804175
Support Care Cancer. 2020 Dec;28(12):5693-5708
pubmed: 32865673
JCO Clin Cancer Inform. 2020 Oct;4:947-957
pubmed: 33112661
Support Care Cancer. 2023 Jan 26;31(2):135
pubmed: 36701006
Support Care Cancer. 2020 Nov;28(11):5455-5461
pubmed: 32166381
Front Digit Health. 2023 Jan 25;4:970112
pubmed: 36761449
Int J Cardiol. 2019 Oct 1;292:280-282
pubmed: 31171391
Support Care Cancer. 2020 Aug;28(8):3467-3475
pubmed: 32342221
J Med Internet Res. 2020 Mar 25;22(3):e12689
pubmed: 32209536
Support Care Cancer. 2023 Jan 10;31(2):108
pubmed: 36625923
Curr Oncol. 2021 Oct 21;28(6):4273-4280
pubmed: 34898539
JMIR Form Res. 2022 May 13;6(5):e37012
pubmed: 35452401
Telemed J E Health. 2020 May;26(5):603-613
pubmed: 31313977
Lancet Oncol. 2019 Dec;20(12):e685-e698
pubmed: 31797795
Support Care Cancer. 2022 Sep;30(9):7665-7678
pubmed: 35689108
Clin Cancer Res. 2021 Feb 15;27(4):933-936
pubmed: 33229457
J Med Internet Res. 2022 Jan 19;24(1):e29635
pubmed: 34907900
Support Care Cancer. 2022 Feb;30(2):1655-1662
pubmed: 34554280
NPJ Digit Med. 2023 May 31;6(1):101
pubmed: 37258851
Ann Oncol. 2019 Feb 1;30(2):167-169
pubmed: 30481270
Support Care Cancer. 2022 Feb;30(2):1007-1010
pubmed: 34668075
Cancer Cell. 2020 Nov 9;38(5):629-646
pubmed: 33049215
JCO Oncol Pract. 2021 Jan;17(1):e11-e15
pubmed: 33434450
NPJ Digit Med. 2020 Aug 27;3:110
pubmed: 32904379
BMC Med Inform Decis Mak. 2018 Jul 27;18(1):70
pubmed: 30053809
Saudi J Anaesth. 2019 Apr;13(Suppl 1):S31-S34
pubmed: 30930717
Support Care Cancer. 2021 Jun;29(6):3025-3034
pubmed: 33037903
Intern Med J. 2021 Jan;51(1):125-133
pubmed: 33572014
JAMA Netw Open. 2021 Nov 1;4(11):e2133877
pubmed: 34817586